nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—Cisplatin—testicular cancer	0.118	0.188	CbGbCtD
Pomalidomide—PTGS2—Etoposide—testicular cancer	0.116	0.185	CbGbCtD
Pomalidomide—ABCB1—Dactinomycin—testicular cancer	0.068	0.108	CbGbCtD
Pomalidomide—CYP3A4—Ifosfamide—testicular cancer	0.0481	0.0763	CbGbCtD
Pomalidomide—CYP1A2—Etoposide—testicular cancer	0.0439	0.0696	CbGbCtD
Pomalidomide—ABCB1—Vinblastine—testicular cancer	0.0426	0.0676	CbGbCtD
Pomalidomide—ABCB1—Cisplatin—testicular cancer	0.039	0.062	CbGbCtD
Pomalidomide—ABCB1—Etoposide—testicular cancer	0.0384	0.0609	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—testicular cancer	0.0262	0.0415	CbGbCtD
Pomalidomide—CYP3A4—Vinblastine—testicular cancer	0.0255	0.0405	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—testicular cancer	0.0253	0.0402	CbGbCtD
Pomalidomide—CYP3A4—Etoposide—testicular cancer	0.023	0.0365	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—testicular cancer	0.0157	0.0249	CbGbCtD
Pomalidomide—CRBN—embryo—testicular cancer	0.00452	0.161	CbGeAlD
Pomalidomide—CRBN—seminal vesicle—testicular cancer	0.00424	0.151	CbGeAlD
Pomalidomide—TNF—lymph node—testicular cancer	0.00335	0.12	CbGeAlD
Pomalidomide—CRBN—gonad—testicular cancer	0.00307	0.109	CbGeAlD
Pomalidomide—CRBN—female gonad—testicular cancer	0.00249	0.0889	CbGeAlD
Pomalidomide—CRBN—testis—testicular cancer	0.00221	0.0788	CbGeAlD
Pomalidomide—CRBN—lymph node—testicular cancer	0.0016	0.0571	CbGeAlD
Pomalidomide—PTGS2—embryo—testicular cancer	0.00123	0.0439	CbGeAlD
Pomalidomide—PTGS2—seminal vesicle—testicular cancer	0.00116	0.0412	CbGeAlD
Pomalidomide—ABCB1—embryo—testicular cancer	0.000761	0.0271	CbGeAlD
Pomalidomide—ABCB1—seminal vesicle—testicular cancer	0.000715	0.0255	CbGeAlD
Pomalidomide—PTGS2—female gonad—testicular cancer	0.000679	0.0242	CbGeAlD
Pomalidomide—ABCB1—gonad—testicular cancer	0.000517	0.0184	CbGeAlD
Pomalidomide—Asthenia—Bleomycin—testicular cancer	0.000457	0.00134	CcSEcCtD
Pomalidomide—Dehydration—Epirubicin—testicular cancer	0.000456	0.00133	CcSEcCtD
Pomalidomide—Skin disorder—Cisplatin—testicular cancer	0.000456	0.00133	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—testicular cancer	0.000455	0.00133	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—testicular cancer	0.000453	0.00133	CcSEcCtD
Pomalidomide—Hyperhidrosis—Cisplatin—testicular cancer	0.000453	0.00133	CcSEcCtD
Pomalidomide—Pruritus—Bleomycin—testicular cancer	0.00045	0.00132	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—testicular cancer	0.000449	0.00131	CcSEcCtD
Pomalidomide—Feeling abnormal—Ifosfamide—testicular cancer	0.000448	0.00131	CcSEcCtD
Pomalidomide—Nausea—Vinblastine—testicular cancer	0.000448	0.00131	CcSEcCtD
Pomalidomide—Hypokalaemia—Epirubicin—testicular cancer	0.000446	0.0013	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000445	0.0013	CcSEcCtD
Pomalidomide—Breast disorder—Epirubicin—testicular cancer	0.000443	0.0013	CcSEcCtD
Pomalidomide—Nasopharyngitis—Epirubicin—testicular cancer	0.000438	0.00128	CcSEcCtD
Pomalidomide—Hypersensitivity—Dactinomycin—testicular cancer	0.000437	0.00128	CcSEcCtD
Pomalidomide—PTGS2—lymph node—testicular cancer	0.000436	0.0156	CbGeAlD
Pomalidomide—Confusional state—Etoposide—testicular cancer	0.000433	0.00127	CcSEcCtD
Pomalidomide—Muscular weakness—Epirubicin—testicular cancer	0.000432	0.00126	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.000432	0.00126	CcSEcCtD
Pomalidomide—Body temperature increased—Ifosfamide—testicular cancer	0.00043	0.00126	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—testicular cancer	0.00043	0.00126	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000427	0.00125	CcSEcCtD
Pomalidomide—Infection—Etoposide—testicular cancer	0.000427	0.00125	CcSEcCtD
Pomalidomide—Asthenia—Dactinomycin—testicular cancer	0.000426	0.00125	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—testicular cancer	0.000425	0.00124	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—testicular cancer	0.000423	0.00124	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—testicular cancer	0.000422	0.00123	CcSEcCtD
Pomalidomide—Thrombocytopenia—Etoposide—testicular cancer	0.000421	0.00123	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000421	0.00123	CcSEcCtD
Pomalidomide—ABCB1—female gonad—testicular cancer	0.00042	0.015	CbGeAlD
Pomalidomide—Dyspnoea—Cisplatin—testicular cancer	0.000418	0.00122	CcSEcCtD
Pomalidomide—Skin disorder—Etoposide—testicular cancer	0.000417	0.00122	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—testicular cancer	0.000416	0.00122	CcSEcCtD
Pomalidomide—Hyperhidrosis—Etoposide—testicular cancer	0.000415	0.00121	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—testicular cancer	0.000413	0.00121	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—testicular cancer	0.00041	0.0012	CcSEcCtD
Pomalidomide—Decreased appetite—Cisplatin—testicular cancer	0.000408	0.00119	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—testicular cancer	0.000407	0.00119	CcSEcCtD
Pomalidomide—Diarrhoea—Dactinomycin—testicular cancer	0.000406	0.00119	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—testicular cancer	0.000406	0.00119	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—testicular cancer	0.000405	0.00119	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000405	0.00118	CcSEcCtD
Pomalidomide—Vomiting—Bleomycin—testicular cancer	0.000405	0.00118	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—testicular cancer	0.000404	0.00118	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—testicular cancer	0.000404	0.00118	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—testicular cancer	0.000402	0.00118	CcSEcCtD
Pomalidomide—Rash—Bleomycin—testicular cancer	0.000401	0.00117	CcSEcCtD
Pomalidomide—Pain—Cisplatin—testicular cancer	0.000401	0.00117	CcSEcCtD
Pomalidomide—Dermatitis—Bleomycin—testicular cancer	0.000401	0.00117	CcSEcCtD
Pomalidomide—Hypersensitivity—Ifosfamide—testicular cancer	0.000401	0.00117	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—testicular cancer	0.0004	0.00117	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.0004	0.00117	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—testicular cancer	0.000397	0.00116	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—testicular cancer	0.000396	0.00116	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000394	0.00115	CcSEcCtD
Pomalidomide—Asthenia—Ifosfamide—testicular cancer	0.00039	0.00114	CcSEcCtD
Pomalidomide—Feeling abnormal—Cisplatin—testicular cancer	0.000386	0.00113	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—testicular cancer	0.000385	0.00113	CcSEcCtD
Pomalidomide—Pruritus—Ifosfamide—testicular cancer	0.000385	0.00113	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—testicular cancer	0.000383	0.00112	CcSEcCtD
Pomalidomide—Dyspnoea—Etoposide—testicular cancer	0.000383	0.00112	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—testicular cancer	0.000382	0.00112	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—testicular cancer	0.000382	0.00112	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—testicular cancer	0.000381	0.00111	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—testicular cancer	0.00038	0.00111	CcSEcCtD
Pomalidomide—Nausea—Bleomycin—testicular cancer	0.000378	0.00111	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—testicular cancer	0.000378	0.0011	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—testicular cancer	0.000378	0.0011	CcSEcCtD
Pomalidomide—Vomiting—Dactinomycin—testicular cancer	0.000377	0.0011	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—testicular cancer	0.000377	0.0011	CcSEcCtD
Pomalidomide—Rash—Dactinomycin—testicular cancer	0.000374	0.00109	CcSEcCtD
Pomalidomide—Decreased appetite—Etoposide—testicular cancer	0.000374	0.00109	CcSEcCtD
Pomalidomide—ABCB1—testis—testicular cancer	0.000372	0.0133	CbGeAlD
Pomalidomide—Diarrhoea—Ifosfamide—testicular cancer	0.000372	0.00109	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—testicular cancer	0.000372	0.00109	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—testicular cancer	0.000371	0.00109	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Etoposide—testicular cancer	0.000371	0.00109	CcSEcCtD
Pomalidomide—Body temperature increased—Cisplatin—testicular cancer	0.000371	0.00108	CcSEcCtD
Pomalidomide—Fatigue—Etoposide—testicular cancer	0.00037	0.00108	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—testicular cancer	0.00037	0.00108	CcSEcCtD
Pomalidomide—Pain—Etoposide—testicular cancer	0.000367	0.00107	CcSEcCtD
Pomalidomide—Constipation—Etoposide—testicular cancer	0.000367	0.00107	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—testicular cancer	0.000367	0.00107	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—testicular cancer	0.000366	0.00107	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000364	0.00107	CcSEcCtD
Pomalidomide—Dizziness—Ifosfamide—testicular cancer	0.00036	0.00105	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—testicular cancer	0.000358	0.00105	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—testicular cancer	0.000357	0.00104	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—testicular cancer	0.000357	0.00104	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—testicular cancer	0.000356	0.00104	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—testicular cancer	0.000355	0.00104	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—testicular cancer	0.000355	0.00104	CcSEcCtD
Pomalidomide—Feeling abnormal—Etoposide—testicular cancer	0.000354	0.00104	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—testicular cancer	0.000354	0.00103	CcSEcCtD
Pomalidomide—Nausea—Dactinomycin—testicular cancer	0.000353	0.00103	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—testicular cancer	0.000351	0.00103	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—testicular cancer	0.000349	0.00102	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—testicular cancer	0.000349	0.00102	CcSEcCtD
Pomalidomide—Vomiting—Ifosfamide—testicular cancer	0.000346	0.00101	CcSEcCtD
Pomalidomide—Hypersensitivity—Cisplatin—testicular cancer	0.000346	0.00101	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—testicular cancer	0.000343	0.001	CcSEcCtD
Pomalidomide—Rash—Ifosfamide—testicular cancer	0.000343	0.001	CcSEcCtD
Pomalidomide—Dermatitis—Ifosfamide—testicular cancer	0.000343	0.001	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000343	0.001	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—testicular cancer	0.00034	0.000993	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—testicular cancer	0.00034	0.000993	CcSEcCtD
Pomalidomide—Asthenia—Cisplatin—testicular cancer	0.000336	0.000984	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—testicular cancer	0.000336	0.000983	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—testicular cancer	0.000335	0.000979	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—testicular cancer	0.000334	0.000977	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—testicular cancer	0.000333	0.000974	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—testicular cancer	0.000332	0.000972	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00033	0.000967	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—testicular cancer	0.00033	0.000964	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—testicular cancer	0.000329	0.000961	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—testicular cancer	0.000326	0.000955	CcSEcCtD
Pomalidomide—Chills—Methotrexate—testicular cancer	0.000325	0.000951	CcSEcCtD
Pomalidomide—Nausea—Ifosfamide—testicular cancer	0.000323	0.000945	CcSEcCtD
Pomalidomide—Diarrhoea—Cisplatin—testicular cancer	0.000321	0.000939	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—testicular cancer	0.000317	0.000928	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—testicular cancer	0.000317	0.000926	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—testicular cancer	0.000315	0.000922	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—testicular cancer	0.000315	0.00092	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—testicular cancer	0.00031	0.000906	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—testicular cancer	0.000309	0.000904	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—testicular cancer	0.000308	0.000902	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—testicular cancer	0.000308	0.000902	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—testicular cancer	0.000308	0.0009	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—testicular cancer	0.000307	0.000899	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—testicular cancer	0.000306	0.000894	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—testicular cancer	0.000305	0.000892	CcSEcCtD
Pomalidomide—Chills—Epirubicin—testicular cancer	0.000304	0.00089	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—testicular cancer	0.000304	0.000889	CcSEcCtD
Pomalidomide—Vomiting—Cisplatin—testicular cancer	0.000298	0.000872	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—testicular cancer	0.000297	0.000869	CcSEcCtD
Pomalidomide—Rash—Cisplatin—testicular cancer	0.000296	0.000865	CcSEcCtD
Pomalidomide—Dermatitis—Cisplatin—testicular cancer	0.000295	0.000864	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—testicular cancer	0.000295	0.000863	CcSEcCtD
Pomalidomide—Diarrhoea—Etoposide—testicular cancer	0.000294	0.00086	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—testicular cancer	0.000291	0.000853	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—testicular cancer	0.000291	0.000852	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—testicular cancer	0.000285	0.000835	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—testicular cancer	0.000285	0.000832	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—testicular cancer	0.000284	0.000831	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—testicular cancer	0.000284	0.00083	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—testicular cancer	0.000283	0.000829	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—testicular cancer	0.000283	0.000827	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—testicular cancer	0.000282	0.000826	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—testicular cancer	0.000281	0.000823	CcSEcCtD
Pomalidomide—Nausea—Cisplatin—testicular cancer	0.000279	0.000815	CcSEcCtD
Pomalidomide—Cough—Methotrexate—testicular cancer	0.000275	0.000805	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—testicular cancer	0.000275	0.000804	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—testicular cancer	0.000273	0.000799	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—testicular cancer	0.000273	0.000799	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—testicular cancer	0.000273	0.000798	CcSEcCtD
Pomalidomide—Rash—Etoposide—testicular cancer	0.000271	0.000792	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—testicular cancer	0.000271	0.000792	CcSEcCtD
Pomalidomide—ABCB1—lymph node—testicular cancer	0.00027	0.00962	CbGeAlD
Pomalidomide—Headache—Etoposide—testicular cancer	0.000269	0.000787	CcSEcCtD
Pomalidomide—Arthralgia—Methotrexate—testicular cancer	0.000268	0.000785	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000267	0.00078	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—testicular cancer	0.000265	0.000776	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—testicular cancer	0.000264	0.000773	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—testicular cancer	0.000264	0.000773	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—testicular cancer	0.000263	0.000768	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—testicular cancer	0.000259	0.000759	CcSEcCtD
Pomalidomide—Cough—Epirubicin—testicular cancer	0.000258	0.000753	CcSEcCtD
Pomalidomide—Infection—Methotrexate—testicular cancer	0.000256	0.000748	CcSEcCtD
Pomalidomide—Nausea—Etoposide—testicular cancer	0.000255	0.000747	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—testicular cancer	0.000252	0.000738	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—testicular cancer	0.000252	0.000738	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—testicular cancer	0.000252	0.000737	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—testicular cancer	0.000251	0.000735	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—testicular cancer	0.00025	0.000732	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—testicular cancer	0.00025	0.000731	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00025	0.00073	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—testicular cancer	0.000249	0.000728	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—testicular cancer	0.000245	0.000718	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—testicular cancer	0.000244	0.000715	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—testicular cancer	0.000243	0.00071	CcSEcCtD
Pomalidomide—Infection—Epirubicin—testicular cancer	0.000239	0.0007	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—testicular cancer	0.000238	0.000697	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—testicular cancer	0.000236	0.000691	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—testicular cancer	0.000236	0.00069	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000234	0.000686	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—testicular cancer	0.000234	0.000684	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—testicular cancer	0.000233	0.000681	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—testicular cancer	0.000233	0.000681	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—testicular cancer	0.000232	0.00068	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—testicular cancer	0.000232	0.000678	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000231	0.000675	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—testicular cancer	0.000229	0.000671	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—testicular cancer	0.000225	0.000657	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—testicular cancer	0.000224	0.000654	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000222	0.00065	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—testicular cancer	0.000222	0.000649	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—testicular cancer	0.000221	0.000648	CcSEcCtD
Pomalidomide—Pain—Methotrexate—testicular cancer	0.00022	0.000644	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000219	0.000642	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—testicular cancer	0.000219	0.000639	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000218	0.000638	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—testicular cancer	0.000218	0.000637	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—testicular cancer	0.000216	0.000633	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—testicular cancer	0.000215	0.00063	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—testicular cancer	0.000215	0.000628	CcSEcCtD
Pomalidomide—Feeling abnormal—Methotrexate—testicular cancer	0.000212	0.00062	CcSEcCtD
Pomalidomide—Decreased appetite—Epirubicin—testicular cancer	0.000209	0.000612	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000208	0.000608	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—testicular cancer	0.000208	0.000607	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—testicular cancer	0.000206	0.000602	CcSEcCtD
Pomalidomide—Pain—Epirubicin—testicular cancer	0.000206	0.000602	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—testicular cancer	0.000203	0.000595	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000203	0.000594	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—testicular cancer	0.000202	0.00059	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—testicular cancer	0.000199	0.000581	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—testicular cancer	0.000198	0.000581	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—testicular cancer	0.000194	0.000567	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000192	0.000563	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—testicular cancer	0.000192	0.000562	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—testicular cancer	0.000191	0.000557	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—testicular cancer	0.000191	0.000557	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—testicular cancer	0.00019	0.000557	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—testicular cancer	0.00019	0.000555	CcSEcCtD
Pomalidomide—Asthenia—Methotrexate—testicular cancer	0.000185	0.00054	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—testicular cancer	0.000184	0.000537	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—testicular cancer	0.000182	0.000533	CcSEcCtD
Pomalidomide—Hypersensitivity—Epirubicin—testicular cancer	0.000177	0.000519	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—testicular cancer	0.000176	0.000515	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—testicular cancer	0.000176	0.000515	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—testicular cancer	0.000173	0.000505	CcSEcCtD
Pomalidomide—Pruritus—Epirubicin—testicular cancer	0.00017	0.000498	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—testicular cancer	0.00017	0.000498	CcSEcCtD
Pomalidomide—Diarrhoea—Epirubicin—testicular cancer	0.000165	0.000482	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—testicular cancer	0.000164	0.00048	CcSEcCtD
Pomalidomide—Vomiting—Methotrexate—testicular cancer	0.000164	0.000479	CcSEcCtD
Pomalidomide—Rash—Methotrexate—testicular cancer	0.000162	0.000475	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—testicular cancer	0.000162	0.000474	CcSEcCtD
Pomalidomide—Headache—Methotrexate—testicular cancer	0.000161	0.000472	CcSEcCtD
Pomalidomide—Asthenia—Doxorubicin—testicular cancer	0.00016	0.000468	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—testicular cancer	0.000159	0.000466	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—testicular cancer	0.000158	0.000461	CcSEcCtD
Pomalidomide—Vomiting—Epirubicin—testicular cancer	0.000153	0.000448	CcSEcCtD
Pomalidomide—Nausea—Methotrexate—testicular cancer	0.000153	0.000447	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—testicular cancer	0.000152	0.000446	CcSEcCtD
Pomalidomide—Rash—Epirubicin—testicular cancer	0.000152	0.000444	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—testicular cancer	0.000152	0.000444	CcSEcCtD
Pomalidomide—Headache—Epirubicin—testicular cancer	0.000151	0.000441	CcSEcCtD
Pomalidomide—Dizziness—Doxorubicin—testicular cancer	0.000147	0.000431	CcSEcCtD
Pomalidomide—Nausea—Epirubicin—testicular cancer	0.000143	0.000418	CcSEcCtD
Pomalidomide—Vomiting—Doxorubicin—testicular cancer	0.000142	0.000414	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—testicular cancer	0.000141	0.000411	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—testicular cancer	0.00014	0.000411	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—testicular cancer	0.00014	0.000408	CcSEcCtD
Pomalidomide—Nausea—Doxorubicin—testicular cancer	0.000132	0.000387	CcSEcCtD
